Innovation Pharmaceuticals Inc (IPIX)

[F1ash]

"“The efficacy of Prurisol was tested in vivo using a human psoriatic skin xenograft model in SCID mice. Endpoints included: appearance, histology, Psoriasis susceptibility-related RNA Gene Induced by Stress [PRINS, Sonkoly, et al. 2005], and blood levels of IL-20, CD4+ T cells, and CD8+ T cells. Activity was compared to standard therapies of methotrexate (MTX), a folate antagonist which inhibits proliferation of psoriatic cells and efalizumab, an immunosuppressive, recombinant humanized anti-CD11a monoclonal antibody that blocks the activation, adhesion, and trafficking of T-cells used in the treatment of psoriasis.”

“ Mice treated with Prurisol showed no reoccurrence of psoriatic lesions during the experiment, whereas animals treated with MTX showed a median reoccurrence of lesions by the 57th day.”

Cellceutix has previously disclosed images of mice treated with Prurisol™ demonstrating its effectiveness as compared to methotrexate, a standard care treatment for psoriasis today.


http://www.cellceutix.com/press-release/2016/11/17/cellceutix-preparing-for-phase-2-clincal-trial-with-new-psoriasis-drug